Viatris Inc. (VTRS): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo dinámico de la innovación farmacéutica, VITRIS Inc. (VTRS) surge como una fuerza transformadora, combinando estratégicamente la destreza de fabricación global, diversas carteras de medicamentos y un compromiso con la atención médica accesible. Al integrar magistralmente los legados de la división Upjohn de Mylan y Pfizer, esta potencia farmacéutica ha creado un modelo de negocio único que ofrece alta calidad, medicamentos rentables en múltiples áreas terapéuticas, revolucionando cómo los pacientes y los proveedores de atención médica abordan las soluciones de tratamiento asequible en todo el mundo.

Viatris Inc. (VTRS) - Modelo de negocio: asociaciones clave

Alianza estratégica con fabricantes farmacéuticos en todo el mundo

VITRIS mantiene alianzas estratégicas con más de 250 fabricantes farmacéuticos en 60 países. La red de fabricación global de la compañía incluye:

Región	Sitios de fabricación	Capacidad de producción anual
América del norte	12 sitios	8.5 mil millones de unidades
Europa	9 sitios	6.2 mil millones de unidades
Asia Pacífico	15 sitios	10.3 mil millones de unidades

Colaboración con distribuidores de atención médica global

VITRIS se asocia con los principales distribuidores de atención médica a nivel mundial, incluyendo:

• McKesson Corporation
• AmerisourceBergen
• Salud cardinal
• Henry Schein

La red de distribución cubre 165 países con más de 7.500 canales de distribución.

Asociación con instalaciones de producción de drogas genéricas

VITRIS colabora con más de 150 instalaciones genéricas de producción de drogas en todo el mundo. Las asociaciones de producción clave incluyen:

Pareja	Enfoque de producción	Volumen anual
Pfizer Centresurce	Ingredientes farmacéuticos activos	2.3 mil millones de unidades
Fabricación de Mylan	Farmacéuticos genéricos	4.100 millones de unidades

Acuerdos de investigación y desarrollo

VITRIS tiene colaboraciones de I + D con 45 instituciones académicas a nivel mundial, que incluyen:

• Instituto de Tecnología de Massachusetts
• Universidad de Stanford
• Universidad de Johns Hopkins
• Universidad de California, San Francisco

Inversión anual de I + D: $ 1.2 mil millones

Empresas conjuntas con compañías farmacéuticas internacionales

VITRIS ha establecido empresas conjuntas con múltiples compañías farmacéuticas internacionales:

Pareja	Enfoque de empresa conjunta	Valor de inversión
Biocon (India)	Desarrollo de biosimilares	$ 300 millones
Lupin Limited	Expansión de medicina genérica	$ 250 millones

Viatris Inc. (VTRS) - Modelo de negocio: actividades clave

Fabricación farmacéutica genérica y especializada global

Instalaciones de fabricación en 6 continentes, con 28 sitios de fabricación a nivel mundial. Capacidad de producción total de aproximadamente 67 mil millones de dosis anuales.

Región de fabricación	Número de sitios	Capacidad de producción anual
América del norte	12	25 mil millones de dosis
Europa	8	18 mil millones de dosis
Asia-Pacífico	6	15 mil millones de dosis
Otras regiones	2	9 mil millones de dosis

Investigación y desarrollo farmacéutico

Inversión en I + D de $ 1.2 mil millones en 2023, centrándose en genéricos complejos y medicamentos especializados.

• Programas de investigación activa en 15 áreas terapéuticas
• Más de 250 proyectos de investigación en curso
• Cartera de patentes de aproximadamente 7.500 patentes activas

Distribución y marketing de productos farmacéuticos

Red de distribución que cubre más de 165 países, con ingresos anuales de $ 16.6 mil millones en 2023.

Canal de distribución	Alcance del mercado	Contribución de ingresos
Farmacias minoristas	120 países	$ 9.4 mil millones
Sistemas hospitalarios	85 países	$ 4.2 mil millones
Directo al paciente	45 países	$ 3 mil millones

Control de calidad y cumplimiento regulatorio

Cumplimiento de los estándares regulatorios en múltiples jurisdicciones, incluidas las directrices de la FDA, EMA y la OMS.

• Aprobó 127 inspecciones regulatorias en 2023
• Cero violaciones de cumplimiento importantes
• Certificación CGMP mantenida en todos los sitios de fabricación

Integración de las operaciones de la división Upjohn de Mylan y Pfizer

Integración de fusión completa con ahorros de sinergia total de $ 1 mil millones para fines de 2023.

Métrica de integración	Valor
Costo de integración total	$ 2.3 mil millones
Ahorros de sinergia	$ 1 mil millones
Base de empleados combinados	37,000
Cartera de productos combinados	1,400+ medicamentos

Viatris Inc. (VTRS) - Modelo de negocio: recursos clave

Infraestructura de fabricación farmacéutica global extensa

VITRIS opera 37 sitios de fabricación a nivel mundial en 6 continentes. La capacidad de fabricación total alcanza los 25 mil millones de dosis anuales.

Ubicación de fabricación	Número de sitios	Capacidad de producción anual
Estados Unidos	12	8.500 millones de dosis
India	9	6.2 mil millones de dosis
Otras ubicaciones internacionales	16	10.3 mil millones de dosis

Cartera diversa de medicamentos genéricos y de marca

VITRIS mantiene una cartera de aproximadamente 1,400 productos aprobados en múltiples áreas terapéuticas.

• Medicamentos genéricos: 1.100 productos
• Medicamentos de marca: 300 productos
• Cobertura en 165 países

Propiedad intelectual y cartera de patentes

A partir de 2023, VITRIS posee 7.500 patentes globales en varias tecnologías y formulaciones farmacéuticas.

Categoría de patente	Número de patentes
Formulaciones farmacéuticas	3,200
Procesos de fabricación	2,100
Tecnologías de entrega	2,200

Fuerza laboral calificada con experiencia farmacéutica

Total de los empleados Recuento: 37,000 a nivel mundial en la investigación, fabricación, ventas y funciones administrativas.

• Empleados con títulos avanzados: 22% (8,140 empleados)
• Científicos de investigación: 1.500
• Representación global de la fuerza laboral: más de 50 nacionalidades

Capacidades avanzadas de investigación y desarrollo

Inversión anual de I + D: $ 1.2 mil millones a partir de 2023.

Área de enfoque de I + D	Inversión	Nuevos desarrollos de moléculas
Desarrollo de drogas genéricas	$ 650 millones	45 moléculas genéricas nuevas
Investigación farmacéutica de marca	$ 400 millones	12 nuevas formulaciones de marca
Tecnologías de entrega avanzadas	$ 150 millones	8 plataformas de entrega novedosas

Viatris Inc. (VTRS) - Modelo de negocio: propuestas de valor

Soluciones de salud asequibles y accesibles

VITRIS reportó ingresos totales de $ 4.7 mil millones en el tercer trimestre de 2023, centrándose en ofrecer soluciones farmacéuticas rentables a nivel mundial.

Categoría de productos	Cuota de mercado global	Precio promedio
Medicamentos genéricos	12.3%	$ 15- $ 45 por receta
Farmacéuticos especiales	7.6%	$ 150- $ 500 por receta

Amplia gama de productos farmacéuticos genéricos y especializados

VITRIS mantiene una cartera de aproximadamente 1,400 productos farmacéuticos diferentes en múltiples áreas terapéuticas.

• Medicamentos cardiovasculares: 215 productos
• Tratamientos respiratorios: 178 productos
• Soluciones de oncología: 92 productos
• Manejo de la diabetes: 86 productos

Medicamentos de alta calidad a precios competitivos

La reducción de precios promedio de la compañía en comparación con las contrapartes de marca varía entre 70-85% en diferentes categorías de medicamentos.

Tipo de medicación	Reducción de precios	Potencial de ahorro anual
Medicamentos de enfermedades crónicas	78%	$ 1.2 mil millones
Medicamentos de tratamiento agudo	72%	$ 850 millones

Cobertura de atención médica global en múltiples áreas terapéuticas

VITRIS opera en más de 165 países con una cartera farmacéutica diversa que aborda múltiples condiciones de salud.

• Cuota de mercado de América del Norte: 42%
• Presencia del mercado europeo: 31%
• Región de Asia-Pacífico: 18%
• América Latina y el resto del mundo: 9%

Alternativa rentable a los productos farmacéuticos de marca

VITRIS generó $ 19.2 mil millones en ingresos totales para el año fiscal 2022, lo que demuestra una importante penetración del mercado a través de alternativas asequibles.

Categoría de productos	Volumen de ventas anual	Ahorro de costos
Equivalentes genéricos	1.200 millones de recetas	$ 4.5 mil millones
Medicamentos biosimilares	218 millones de recetas	$ 1.8 mil millones

Viatris Inc. (VTRS) - Modelo de negocios: relaciones con los clientes

Ventas directas a proveedores e instituciones de atención médica

VITRIS reportó $ 4.2 mil millones en ventas farmacéuticas globales en el tercer trimestre de 2023. Los canales de venta directos incluyen:

Canal de ventas	Ingresos anuales
Sistemas hospitalarios	$ 1.3 mil millones
Farmacias minoristas	$ 2.1 mil millones
Proveedores de atención especializada	$ 780 millones

Plataformas de atención al cliente en línea e información

La infraestructura de soporte digital incluye:

• Portal del paciente en línea 24/7 con 1.2 millones de usuarios registrados
• Aplicación móvil con funciones de seguimiento de medicamentos
• Tiempo de respuesta del servicio al cliente: promedio de 12 minutos

Programas de asistencia para el paciente y acceso a medicamentos

VITRIS ofrece programas integrales de apoyo al paciente:

Tipo de programa	Pacientes atendidos	Inversión anual
Asistencia financiera	275,000 pacientes	$ 62 millones
Acceso a la medicación	340,000 pacientes	$ 45 millones

Participación digital a través de redes profesionales de atención médica

Métricas de compromiso profesional:

• Plataforma digital profesional de la salud: 87,000 usuarios registrados
• Webinarios web de educación médica continua: 42 sesiones en 2023
• Tasa de interacción digital: 68% de compromiso

Servicios de consulta de medicamentos personalizados

Estadísticas de servicio de consulta:

Tipo de servicio	Consultas realizadas	Duración promedio
Consultas telefónicas	156,000 anualmente	22 minutos
Consultas de video	94,000 anualmente	18 minutos

Viatris Inc. (VTRS) - Modelo de negocio: canales

Mayoristas y distribuidores farmacéuticos

VITRIS distribuye productos farmacéuticos a través de los principales mayoristas con las siguientes asociaciones clave:

Mayorista	Cuota de mercado	Volumen de distribución anual
AmerisourceBergen	26.7%	$ 214.5 mil millones (2023)
McKesson Corporation	22.3%	$ 189.7 mil millones (2023)
Salud cardinal	19.5%	$ 165.2 mil millones (2023)

Representantes de ventas directas

VITRIS mantiene una fuerza de ventas directa robusta con las siguientes características:

• Representantes de ventas totales: 3.200
• Cobertura geográfica: 60 países
• Ventas promedio por representante: $ 1.4 millones anuales

Mercados farmacéuticos en línea

Los canales de distribución digital incluyen:

Plataforma	Volumen de ventas en línea	Penetración del mercado
Farmacia de Amazon	$ 1.2 mil millones (2023)	15.3%
Walgreens en línea	$ 890 millones (2023)	11.7%

Redes de proveedores de atención médica

VITRIS colabora con redes de atención médica a través de asociaciones estratégicas:

• Asociaciones del sistema hospitalario: 742
• Conexiones de red clínica: 1.356
• Alcance total del proveedor de atención médica: 58,000 instituciones

Plataformas de marketing digital y comercio electrónico

Marketing digital y canales de ventas Rendimiento:

Canal	Ingreso digital	Índice de crecimiento
Sitio web de la empresa	$ 213 millones (2023)	14.2%
Comercio electrónico de terceros	$ 467 millones (2023)	22.6%

VITRIS Inc. (VTRS) - Modelo de negocio: segmentos de clientes

Instituciones y hospitales de atención médica

VITRIS sirve aproximadamente 180,000 instalaciones de atención médica a nivel mundial. La cartera de productos de la compañía incluye más de 7,500 productos farmacéuticos genéricos y de marca distribuidos en redes hospitalarias.

Segmento de mercado	Número de instalaciones	Valor de adquisición anual
Hospitales de cuidados agudos	65,000	$ 2.3 mil millones
Hospitales comunitarios	45,000	$ 1.7 mil millones
Centros de atención médica especializados	70,000	$ 1.5 mil millones

Farmacias minoristas

VITRIS mantiene relaciones con más de 250,000 ubicaciones de farmacia minorista en todo el mundo.

• Farmacias de cadena: 55,000 ubicaciones
• Farmacias independientes: 180,000 ubicaciones
• Farmacias especializadas: 15,000 ubicaciones

Pacientes individuales que requieren medicamentos genéricos

VITRIS atiende a aproximadamente 1.300 millones de pacientes a nivel mundial a través de su cartera de medicamentos genéricos.

Demografía del paciente	Número de pacientes	Valor de prescripción promedio
Pacientes con enfermedades crónicas	620 millones	$87
Pacientes de cuidados agudos	430 millones	$45
Pacientes de cuidados preventivos	250 millones	$62

Profesionales de la salud y médicos

VITRIS se involucra con aproximadamente 2.5 millones de profesionales de la salud a nivel mundial.

• Médicos de atención primaria: 1.2 millones
• Especialistas: 680,000
• Farmacéuticos: 420,000
• Enfermeras practicantes: 200,000

Organizaciones de atención médica del gobierno

VITRIS colabora con sistemas de atención médica en 165 países.

Segmento gubernamental	Número de contratos	Valor anual del contrato
Sistemas nacionales de atención médica	87	$ 3.6 mil millones
Programas de salud estatales/provinciales	412	$ 1.9 mil millones
Iniciativas de salud pública	156	$ 780 millones

Viatris Inc. (VTRS) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

En el año fiscal 2022, VITRIS reportó gastos de I + D de $ 1.0 mil millones, lo que representa aproximadamente el 6.7% de los ingresos totales.

Año	Gastos de I + D	Porcentaje de ingresos
2022	$ 1.0 mil millones	6.7%
2021	$ 1.1 mil millones	7.2%

Costos de fabricación y producción

VITRIS opera 40 instalaciones de fabricación a nivel mundial, con gastos de fabricación totales de $ 5.8 mil millones en 2022.

• Sitios de fabricación totales: 40
• Instalaciones de fabricación ubicadas en: Estados Unidos, India, Europa y Asia
• El costo de fabricación por unidad varía entre $ 0.50- $ 15 dependiendo de la complejidad del producto

Distribución global y logística

Los costos de distribución para VITRIS en 2022 fueron de aproximadamente $ 1.2 mil millones, que cubren las operaciones globales de la cadena de suministro.

Región de distribución	Gastos logísticos
América del norte	$ 480 millones
Europa	$ 350 millones
Asia-Pacífico	$ 270 millones
Resto del mundo	$ 100 millones

Cumplimiento regulatorio y control de calidad

VITRIS invirtió $ 350 millones en cumplimiento regulatorio y medidas de control de calidad en 2022.

• Tamaño del equipo de cumplimiento: más de 500 profesionales
• Presupuesto de control de calidad: $ 350 millones
• Costos de auditoría regulatoria anual: $ 50 millones

Gastos operativos de marketing y ventas

Los gastos de marketing y ventas para VITRIS totalizaron $ 2.1 mil millones en 2022.

Categoría de gastos	Cantidad
Compensación de la fuerza de ventas	$ 1.2 mil millones
Campañas de marketing	$ 600 millones
Marketing digital	$ 300 millones

Viatris Inc. (VTRS) - Modelo de negocios: flujos de ingresos

Venta de productos farmacéuticos genéricos

Ingresos farmacéuticos genéricos totales para VITRIS en 2022: $ 10.1 mil millones

Categoría de productos	Ingresos ($ M)
Genéricos sólidos orales	4,750
Genéricos inyectables	2,300
Genéricos tópicos	1,250

Ingresos de medicamentos especializados

Ventas de medicamentos especializados en 2022: $ 3.8 mil millones

• Las marcas de especialidad clave incluyen Modufiq y Yentreve
• Segmento de crecimiento más alto dentro de la cartera de VITRIS

Acuerdos de licencia y propiedad intelectual

Ingresos totales de licencia de IP en 2022: $ 450 millones

Pareja	Tipo de acuerdo	Valor ($ m)
Pfizer	Desarrollo de drogas	175
Novartis	Transferencia de tecnología	135

Servicios de fabricación de contratos

Ingresos de fabricación por contrato en 2022: $ 675 millones

• Servicios de fabricación para 37 compañías farmacéuticas
• Capacidad de producción: 25 sitios de fabricación global

Ventas de expansión del mercado internacional

Desglose de ingresos internacionales para 2022: $ 6.2 mil millones

Región	Ingresos ($ M)	Porcentaje
América del norte	3,700	59.7%
Europa	1,250	20.2%
Asia-Pacífico	850	13.7%
Resto del mundo	400	6.4%

Viatris Inc. (VTRS) - Canvas Business Model: Value Propositions

Access to high-quality, affordable medicines at scale globally is a core proposition for Viatris Inc. The company states it supplies high-quality medicines to approximately 1 billion patients around the world annually.

The global footprint supports this scale, with Viatris Inc. serving patients in more than 165+ Countries & Territories. The operational structure includes global centers in Pittsburgh, Shanghai, and Hyderabad, India, supporting this reach. The manufacturing and packaging network comprises 26 facilities globally, with an annual dose capacity exceeding 80BN+ units.

The value proposition rests on a diversified portfolio mitigating risk across generics and established brands. For instance, in the second quarter of 2025, the company reported an Adjusted Gross Margin of 56.6%, reflecting the mix of its offerings. Total revenues for that quarter were $3.58 billion, with divestiture-adjusted operational revenue growth of approximately 3% year-over-year when excluding the negative impact from the Indore facility.

Reliability of supply is underpinned by this global network. While the company faced a significant regulatory hurdle at its Indore facility, which management estimated would negatively impact 2025 total revenues by approximately $500 million, the company still reported a 93% Customer service delivery in full and on-time capacity in historical data, highlighting the intended reliability of the broader system. [The company is focused on remediation efforts at the Indore facility as of late 2025.]

New product introductions are a key driver for future value, with Viatris Inc. expecting these to generate $450 million to $550 million in 2025. This target follows 2024 new product revenues of $582 million. The company is also focused on bridging the divide between generics and innovative, patent-protected assets, evidenced by pipeline progress including six Phase 3 data readouts anticipated in 2025 for assets like selatogrel, cenerimod, and sotagliflozin.

Here's a look at the scale supporting the global access value proposition:

Metric	Value
Patients Served Annually	Approximately 1 billion
Countries & Territories Served	165+
Manufacturing & Packaging Facilities	26
Annual Dose Capacity	80BN+
2025 New Product Revenue Target (Midpoint)	$500 million

The company's financial strength, which allowed for a $3.7 billion debt reduction in 2024, underpins the ability to commit to shareholder returns, with a 2025 plan targeting $500 million to $650 million in share repurchases.

The portfolio segments contributing to this value include:

• Brands net sales showing strength in Greater China and Emerging Markets.
• Generics net sales supported by complex products in North America.
• Continued solid performance across the broader European portfolio.

Finance: review the impact of the raised 2025 revenue guidance midpoint of $14,100 million against the prior full-year 2024 revenue of $14.7 billion.

Viatris Inc. (VTRS) - Canvas Business Model: Customer Relationships

You're looking at how Viatris Inc. manages its connections with the diverse groups it serves-from doctors writing prescriptions to governments buying bulk supplies. Honestly, in pharma, relationships are about access and reliability, especially when you're dealing with both established generics and a growing specialty pipeline.

Dedicated sales forces engaging physicians and pharmacists globally

Viatris Inc. structures its commercial engagement to support its dual focus on generics and established brands across its global footprint. While the exact size of the dedicated sales force isn't publicly itemized for late 2025, the company's strategy involves leveraging its commercial infrastructure to drive adoption for its expanding portfolio, including late-stage assets.

The focus areas for commercial execution in 2025 include:

• Driving strong commercial execution across markets.
• Focusing on therapeutic areas with unmet needs.
• Anticipating new product revenues between $450 million and $550 million for the full year 2025.

Patient support and education programs for complex therapies

Viatris Inc. maintains several programs aimed at ensuring patients can access and properly use their medications, particularly for complex or chronic conditions. This support builds a crucial bridge between the product and the patient experience.

Concrete examples of this commitment include:

• Sponsoring the Congressional Women's Softball Game, which, as of 2025, has raised over $4.5 million for the Young Survival Coalition, supporting young adults with breast cancer.
• Supporting educational programs for cystic fibrosis families regarding family building processes.
• Continuing support for the National MS Society's MS Navigators® Program, which in 2022 supported over 46,500 individuals directly with services like insurance and social support.

The Viatris Patient Assistance Program offers certain medicines for free to patients demonstrating financial need, covering medications like Arixtra®, Breyna®, and Wixela® across Group 1 and Group 2 classifications.

Key account management for large government purchasers and NGOs

Viatris Inc. manages relationships with large-scale purchasers, including public and governmental agencies, alongside its work with retail chains and wholesalers. This segment requires navigating complex procurement policies, which sometimes include social and environmental requirements.

The company's participation in initiatives like Europe's Critical Medicines Alliance, launched in April 2024, directly addresses the need for stable access to essential medicines for large purchasers and public health systems.

High-touch, expert support for innovative and specialty products

As Viatris Inc. advances its pipeline, the need for high-touch support for innovative and specialty products increases. The company is positioning itself for future growth by advancing assets like selatogrel, cenerimod, and sotagliflozin, expecting six Phase 3 data readouts in 2025.

This focus on innovation requires commercial capabilities aligned with specialty care, which is a key part of the strategy to accelerate growth. The company is also pursuing targeted, accretive business development opportunities that leverage its existing commercial infrastructure.

Maintaining supply chain reliability to build defintely customer trust

Supply chain reliability is a direct driver of customer trust, especially when operational challenges arise. Viatris Inc. is actively managing the impact of the FDA warning letter related to its oral finished dose manufacturing facility in Indore, India, which is a significant factor affecting customer confidence and near-term financials.

Here is a look at the financial context impacting supply chain trust in 2025:

Metric	2025 Projection/Impact	Source Context
Estimated Negative Impact on Total Revenues (FY 2025)	Approximately $500 million	Due to the Indore facility issue.
Estimated Negative Impact on Adjusted EBITDA (FY 2025)	Approximately $385 million	Due to the Indore facility issue.
Estimated Indore Impact on Q3 2025 Total Revenues	Approximately $100 million	Reported for the three months ended September 30, 2025.
Projected Full Year 2025 Total Revenues	Between $13.5 billion and $14.0 billion	Overall financial guidance.
Projected Full Year 2025 U.S. GAAP Net Cash from Operations (Midpoint)	Approximately $2.325 billion	Updated guidance as of November 6, 2025.

Viatris Inc. is working closely with its customers to mitigate potential supply disruptions and expects remediation efforts at the Indore facility to be completed soon, with an anticipated request for FDA reinspection. The company is focused on operational resilience to ensure it meets the needs of patients and customers.

Finance: draft 13-week cash view by Friday.

Viatris Inc. (VTRS) - Canvas Business Model: Channels

You're looking at how Viatris Inc. gets its products-from established brands to generics-into the hands of patients and healthcare providers globally. This is all about the physical and contractual pathways they use, which are heavily segmented by geography. The company's commercial infrastructure is designed to support patients in more than 165 countries and territories.

The primary channel strategy is built around its four core commercial segments, which dictate the go-to-market approach. For instance, the Developed Markets channel relies heavily on direct sales to wholesalers, distributors, and pharmacies, which is the typical route for established pharmaceutical products in mature economies like the United States, Canada, and Europe.

To give you a concrete idea of where the revenue flows through these channels, here's a look at the geographic revenue distribution based on recent reporting periods, which shows the weight of the Developed Markets channel:

Commercial Segment	Revenue Amount (Approximate)	Percentage of Total Revenue (Contextual)
Developed Markets	$8.96B	60.8%
Emerging Markets	$2.26B	15.3%
Greater China	$2.17B	14.7%
Japan, Australia and New Zealand (JANZ)	$1.35B	9.2%

In contrast, the channel strategy in Emerging Markets often leans more heavily on government tenders and institutional sales, especially given that this segment includes over 125 developing countries. This approach is crucial for volume and access in regions with different procurement structures. The company expects to deliver between $450 million and $550 million in new product revenues in 2025, which will flow through these established channels, building on the $582 million in new product revenues generated in 2024.

The structure of these channels supports the different product categories Viatris Inc. moves. For example, Brands net sales show strength in Greater China and Emerging Markets, suggesting successful localized distribution and market access efforts there. Generics net sales, meanwhile, reflect strong growth from new product performance in Developed Markets, indicating the established wholesaler/pharmacy channel is effectively absorbing new generic launches.

The company also employs direct-to-consumer marketing and digital engagement for select brands, though the primary focus remains on business-to-business distribution. The overall channel effectiveness is supported by a global infrastructure. Here are the key components defining the commercial reach:

• Developed Markets: Includes the United States, Canada, and Europe.
• Greater China: Covers Mainland China, Hong Kong, and Taiwan.
• JANZ: Japan, Australia, and New Zealand.
• Emerging Markets: Encompasses over 125 developing countries.
• Global Footprint: Supports patient access in more than 165 Countries & Territories.

The total revenue for the twelve months ending September 30, 2025, was $14.124B, illustrating the scale these channels manage. The success of the channel strategy is defintely tied to navigating the regulatory and logistical differences across these diverse markets.

Viatris Inc. (VTRS) - Canvas Business Model: Customer Segments

You're looking at the core groups Viatris Inc. sells its medicines to as of late 2025. This isn't just about who buys the pill; it's about the entire healthcare ecosystem that needs cost-effective, accessible treatments.

Viatris Inc. serves a massive global base, reaching approximately 1 billion patients annually with its diverse portfolio of branded, generic, and biosimilar products. The company's strategy clearly segments its approach based on the buyer's primary need-be it price, access, or formulary inclusion.

Here's a look at the key customer segments Viatris Inc. targets:

• Governments and Non-Governmental Organizations (NGOs) for essential medicines
• Wholesalers, distributors, and large pharmacy chains globally
• Patients with chronic conditions requiring long-term, affordable treatment
• Healthcare providers (HCPs) prescribing a broad range of generics and brands
• Health systems and payers seeking cost-effective pharmaceutical solutions

For the health systems and payers, the focus is definitely on cost-effectiveness and getting products onto their approved lists (formulary inclusion). For patients, trust in the medication and affordability, especially for ongoing chronic care, drives the purchase. It's a delicate balance, and Viatris Inc. is positioning its pipeline to support this dual need.

The company's geographic focus also dictates customer interaction. While Developed Markets drive generics growth, Emerging Markets and Greater China show robust expansion for established brands. To be fair, the operational disruption at the Indore facility in early 2025, which was estimated to reduce total revenues by approximately $500 million for the full year, highlights the importance of supply chain reliability across all these segments.

Here are some key figures related to Viatris Inc.'s scale and financial commitments to its stakeholders, which indirectly reflect the scale of its customer base:

Metric	2025 Data Point	Context
Full Year 2025 Revenue Guidance Midpoint	$13.75 billion	Total Revenues expected between $13.5 billion and $14.0 billion.
Q3 2025 Total Revenues	$3.8 billion	Reported total revenues for the third quarter of 2025.
Projected 2025 New Product Revenues	$450 million to $550 million	Revenue expected from new product launches in 2025.
YTD Capital Returned to Shareholders (as of Q3 2025)	More than $920 million	Includes dividends and share repurchases year-to-date.
Planned 2025 Share Repurchases	$500 million to $650 million	Allocation for capital return priority in 2025.
US Revenue Sourcing	More than half	Percentage of US revenue sourced domestically.

For the segment of Healthcare Providers (HCPs), Viatris Inc. is advancing its pipeline, expecting six Phase 3 data readouts in 2025 for assets including selatogrel, cenerimod, and sotagliflozin, which speaks directly to the future prescriptions HCPs will write. Also, the company continues to advocate strongly for thoughtful policymaking that protects access to generics, which account for 90% of prescriptions filled in the United States.

The segment dealing with wholesalers and distributors values supply chain reliability above all else. Viatris Inc. operates in approximately 165 countries, so managing this global distribution network is a key operational function supporting this customer group. They are defintely focused on execution.

Finance: draft 13-week cash view by Friday.

Viatris Inc. (VTRS) - Canvas Business Model: Cost Structure

When you look at Viatris Inc.'s cost structure, you're looking at the realities of running a massive, global, post-merger pharmaceutical company. The costs are inherently high because of the scale and the complexity of the products they manage.

High Cost of Goods Sold (COGS) due to global manufacturing and raw materials

While the exact Cost of Goods Sold (COGS) figure for 2025 isn't explicitly broken out in the guidance summaries, the scale of Viatris Inc.'s operations implies a substantial COGS component, which directly impacts the gross margin. The company's global supply chain, designed to reach about 1 billion patients annually, involves sourcing raw materials and manufacturing across numerous sites, which naturally carries significant variable costs. The focus on improving commercial execution and managing the global infrastructure review suggests an ongoing effort to optimize these production costs.

• Full Year 2024 Adjusted EBITDA was reported at $4.7 billion.
• The midpoint of the 2025 total revenues guidance was set at $13.75 billion.
• For the first six months of 2025, the estimated negative impact from the Indore facility on total revenues was $300 million.

Significant investment in Research and Development (R&D) for pipeline advancement

Viatris Inc. has to spend to keep its portfolio fresh, even though it is heavily focused on generics and established brands. The R&D spend is directed toward advancing the pipeline, which is a necessary, ongoing cost. Management is clearly prioritizing late-stage assets, which often require significant clinical trial expenditure.

• The company expects six Phase 3 trials to read out in 2025.
• The 2025 new product revenue target is set between $450 million and $550 million, which is a direct result of prior R&D investment.
• Adjusted R&D as a percentage of total revenues is a key non-GAAP metric tracked for comparability, reflecting the ongoing investment level.

Selling, General, and Administrative (SG&A) expenses for the global commercial footprint

SG&A covers the cost of selling and marketing the vast portfolio across different geographies, plus the overhead of running the corporate structure. You can see the scale of this cost base by looking at the trailing twelve months (TTM) data. This is a fixed-to-semi-variable cost that the company is actively trying to manage through its global infrastructure review.

Period	SG&A Expense Amount
Full Year 2024	$4.426 billion
TTM ending June 30, 2025	$4.248 billion

The TTM figure shows a decline, which is a positive sign for cost control efforts.

Costs associated with facility remediation and regulatory compliance (e.g., Indore)

This is a major, non-recurring, but significant, cost head for Viatris Inc. in 2025. The FDA warning letter and import alert at the oral solid dose manufacturing facility in Indore, India, created direct financial hits and remediation expenses. As of late 2025, the initial corrective work is reported as 'substantially complete,' but the financial bleed has been real.

• Estimated negative impact on 2025 Adjusted EBITDA is $385 million.
• The revenue impact in the first quarter of 2025 alone was approximately $140 million.
• The company is preparing for an expected FDA re-inspection sometime in 2026.

Interest expense on substantial debt load

Servicing the debt remains a key cost. While the company made significant progress in paying down debt in 2024, the remaining balance still generates material interest expense. Adjusted interest expense is tracked, but the absolute dollar amount for 2025 is not provided in the guidance documents, so we look at the debt reduction as the primary context for this cost.

• Viatris Inc. paid down $3.7 billion in debt during the full year 2024.
• The long-term gross leverage target was hit by the end of 2024, ending at 2.9 times leverage.
• The company is prioritizing capital return in 2025, planning share repurchases of $500 million to $650 million, which is a shift in capital allocation away from further debt reduction.

Finance: draft 13-week cash view by Friday.

Viatris Inc. (VTRS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Viatris Inc. brings in money as of late 2025. It's a mix of legacy, off-patent brands and the high-volume generics business.

Revenue Stream Component	Financial Data Point (2025 Projection unless noted)
Net sales from Established Brands (e.g., Lipitor, Viagra)	2024 Total Revenue: $14.7 billion
Net sales from Generics and Complex Generics	2024 Total Revenue: $14.7 billion
Total Revenue projected to be between $13.9 billion and $14.3 billion for 2025	$13.9 billion and $14.3 billion
Revenue from new product launches and regional licensing deals	New Product Revenues: $450 million to $550 million

The company is definitely prioritizing shareholder returns alongside navigating near-term operational headwinds, like the estimated negative impact from the Indore facility issues on 2025 revenues.

• Quarterly dividend payments to shareholders of $0.12 per share
• Annual 2025 dividend policy approved at $0.48 per share
• Capital return plan includes $500 million to $650 million in share repurchases for 2025

The expectation for new product revenues in 2025 is between $450 million and $550 million. That's a key driver as the legacy brands continue to face patent expirations and market competition.